Panavance Therapeutics Inc.
Hanns Mohler serves as the Head of Pharmacology at Panavance Therapeutics Inc. since March 2022 and is a Professor em. of Pharmacology at the Institute of Pharmacology, ETH Zurich, and University of Zurich since April 1988. Mohler has held various prestigious roles, including Professor of Pharmacology and Director, while also being a member of both the Swiss Academy of Medical Sciences and the European Academy of Sciences (Academia Europaea). Previous positions include Senior Consultant roles at Geistlich Pharma AG, GSK Verona, and Roche, as well as a consulting position with HBM Bioventures. Before these roles, Mohler was a Professor of Biochemistry at the University of Freiburg and Vice Director (Science) at Roche's Research Department. Education includes a Dr. rer. nat. in Biochemistry from multiple esteemed institutions, including the Universities of Tübingen and Freiburg.
This person is not in any offices
Panavance Therapeutics Inc.
Panavance Therapeutics Inc. is a US, clinical-stage pharmaceutical company established in 2021 by the Swiss-based Avensis Pharma AG, a subsidiary of Ed. Geistlich Söhne AG für Chemische Industrie. Panavance is focused on advancing the development of GP-2250, a novel oncology therapeutic intended to improve outcomes and quality of life for patients with cancer. With its highly capable team and strong academic and industry partnerships, Panavance is pursuing a rigorous program to bring GP-2250 to patients around the world.